Patents by Inventor Michael Mutz

Michael Mutz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130224288
    Abstract: The invention relates to the F-crystal form, G-crystal form, H-crystal form, I-crystal form and K-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans.
    Type: Application
    Filed: July 15, 2011
    Publication date: August 29, 2013
    Inventor: Michael Mutz
  • Patent number: 8513256
    Abstract: The present invention relates to acid addition salts of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, which are selected from the group consisting of a tartrate salt, such as a (D)(?) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt, a citrate salt, a malate salt, a fumarate salt, a succinate salt, a benzoate salt, a benzenesulfonate salt, a pamoate salt, a formate salt, a malonate salt, a 1,5-naphthalenedisulfonate salt, a salicylate salt, a cyclohexanesulfamate salt, a lactate salt, a mandelate salt, aq glutarate salt, an adipate salt, a squarate salt, a vanillate salt, an oxaloacetate salt, an ascorbate salt and a sulfate salt.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: August 20, 2013
    Assignee: Novartis AG
    Inventors: Hans Michael Bürger, Paul William Manley, Michael Mutz
  • Patent number: 8507515
    Abstract: Crystalline forms of imatinib mesylate (F, G, H, I and K) and their respective characterization are disclosed.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: August 13, 2013
    Assignee: Novartis AG
    Inventor: Michael Mutz
  • Patent number: 8487095
    Abstract: The present invention relates to new salt forms of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide, in particular the mesylate, hydrochloride, tartrate, phosphate and hemi fumarate salt thereof; to crystalline forms of such salts; to polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide; to hydrates and polymorphs of the new salt forms mentioned above; to the use of the new salt forms mentioned above for the manufacture of a medicament for the treatment of a disorder mediated by Hsp90; to a method for treating a disorder mediated by Hsp90 using the new salt forms; to formulations comprising such salt forms, in particular aqueous solutions suitable for intravenous administration; and to amber glass containers being filled with such formulations.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: July 16, 2013
    Assignees: Novartis AG
    Inventors: Martin James Drysdale, Brian William Dymock, Christoph Krell, Michael Mutz, Holger Petersen, Weijia Zheng
  • Patent number: 8436030
    Abstract: The invention relates to crystalline forms of 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid and to its amorphous form, to processes for the preparation thereof, to compositions containing the same and their uses for the manufacture of a medicament for the treatment of the human body.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: May 7, 2013
    Assignee: Navartis AG
    Inventor: Michael Mutz
  • Publication number: 20130060029
    Abstract: There is described a process for the manufacture of compounds of the formula I said process comprising reacting a compound of the formula II as described herein, or a salt thereof, under simultaneous or sequential condensation and cyclisation conditions with an aniline compound of the formula III, wherein R2 and m are as defined for a compound of the formula I. Further reactions and related embodiments are also claimed and disclosed.
    Type: Application
    Filed: September 12, 2012
    Publication date: March 7, 2013
    Inventors: Weichun Chen, Hong-Yong Kim, Jessica Liang, Michael Mutz, Mahavir Prashad, Christopher Towler, Ruoqiu Wu
  • Publication number: 20130022672
    Abstract: The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of lmatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.
    Type: Application
    Filed: September 24, 2012
    Publication date: January 24, 2013
    Applicant: NOVARTIS AG
    Inventors: Elisabete Goncalves, Oskar Kalb, Michael Mutz, Wolfgang Wirth, Jay Parthiban Lakshman
  • Patent number: 8349852
    Abstract: There is described a new polymorphic form of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and a method of preparing it.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: January 8, 2013
    Assignee: Novartis AG
    Inventors: Weichun Chen, Hong-Yong Kim, Jessica Liang, Michael Mutz, Mahavir Prashad, Christopher Towler, Ruoqiu Wu
  • Publication number: 20120322789
    Abstract: The invention relates to a new crystalline form II of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of crystalline form II of of N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. The invention relates to the amorphous forms of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of amorphous N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.
    Type: Application
    Filed: May 15, 2012
    Publication date: December 20, 2012
    Inventors: Pascale HOEHN, Bernd KOCH, Michael MUTZ
  • Publication number: 20120226038
    Abstract: The invention relates to particular crystal forms of the methanesulfonic acid addition salt of 4-(4-methyl piperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, and their use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans.
    Type: Application
    Filed: May 15, 2012
    Publication date: September 6, 2012
    Inventor: Michael Mutz
  • Publication number: 20120203007
    Abstract: The invention relates to crystalline forms of 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid and to its amorphous form, to processes for the preparation thereof, to compositions containing the same and their uses for the manufacture of a medicament for the treatment of the human body.
    Type: Application
    Filed: February 27, 2012
    Publication date: August 9, 2012
    Applicant: NOVARTIS AG
    Inventor: Michael Mutz
  • Publication number: 20120172592
    Abstract: The present invention relates to new salt forms of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide, in particular the mesylate, hydrochloride, tartrate, phosphate and hemi fumarate salt thereof; to crystalline forms of such salts; to polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide; to hydrates and polymorphs of the new salt forms mentioned above; to the use of the new salt forms mentioned above for the manufacture of a medicament for the treatment of a disorder mediated by Hsp90; to a method for treating a disorder mediated by Hsp90 using the new salt forms; to formulations comprising such salt forms, in particular aqueous solutions suitable for intravenous administration; and to amber glass containers being filled with such formulations.
    Type: Application
    Filed: March 8, 2012
    Publication date: July 5, 2012
    Inventors: Martin James Drysdale, Brian William Dymock, Christoph Krell, Michael Mutz, Holger Petersen, Weijia Zheng
  • Patent number: 8198289
    Abstract: The invention relates to particular crystal forms of the methanesulfonic acid addition salt of 4-(4 -methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, and their use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: June 12, 2012
    Assignees: Novartis AG, Novartis Pharma GmbH
    Inventor: Michael Mutz
  • Patent number: 8198435
    Abstract: The invention relates to a new crystalline form II of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of crystalline form II of N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. The invention relates to the amorphous forms of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of amorphous N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: June 12, 2012
    Assignee: Novartis AG
    Inventors: Pascale Hoehn, Bernd Koch, Michael Mutz
  • Publication number: 20120142697
    Abstract: The present invention relates to acid addition salts of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, which are selected from the group consisting of a tartrate salt, such as a (D)(?) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt, a citrate salt, a malate salt, a fumarate salt, a succinate salt, a benzoate salt, a benzenesulfonate salt, a pamoate salt, a formate salt, a malonate salt, a 1,5-naphthalenedisulfonate salt, a salicylate salt, a cyclohexanesulfamate salt, a lactate salt, a mandelate salt, aq glutarate salt, an adipate salt, a squarate salt, a vanillate salt, an oxaloacetate salt, an ascorbate salt and a sulfate salt.
    Type: Application
    Filed: February 8, 2012
    Publication date: June 7, 2012
    Inventors: Hans Michael Bürger, Paul William Manley, Michael Mutz
  • Patent number: 8178566
    Abstract: The invention relates to new crystal forms of epothilone B.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: May 15, 2012
    Assignee: Novartis AG
    Inventors: Ernst Küsters, Michael Mutz, Frank Stowasser
  • Publication number: 20120115840
    Abstract: This invention relates to a hemifumarate salt of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment. In addition, the present invention also relates to new polymorphic forms of the hemifumarate salt form of Compound I, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.
    Type: Application
    Filed: December 16, 2009
    Publication date: May 10, 2012
    Inventors: Lech Ciszewski, Marilyn De La Cruz, Piotr H. Karpinski, Michael Mutz, Christian Riegert, Caspar Vogel, Ricardo Schneeberger
  • Patent number: 8163747
    Abstract: The present invention relates to new salt forms of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide, in particular the mesylate, hydrochloride, tartrate, phosphate and hemi fumarate salt thereof; to crystalline forms of such salts; to polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide; to hydrates and polymorphs of the new salt forms mentioned above; to the use of the new salt forms mentioned above for the manufacture of a medicament for the treatment of a disorder mediated by Hsp90; to a method for treating a disorder mediated by Hsp90 using the new salt forms; to formulations comprising such salt forms, in particular aqueous solutions suitable for intravenous administration; and to amber glass containers being filled with such formulations.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: April 24, 2012
    Assignees: Novartis AG, Vernalis (R&D) Ltd.
    Inventors: Martin James Drysdale, Brian William Dymock, Christoph Krell, Michael Mutz, Holger Petersen, Weijia Zheng
  • Patent number: 8153672
    Abstract: The invention relates to crystalline forms of 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid and to its amorphous form, to processes for the preparation thereof, to compositions containing the same and their uses for the manufacture of a medicament for the treatment of the human body.
    Type: Grant
    Filed: November 27, 2007
    Date of Patent: April 10, 2012
    Assignee: Novartis AG
    Inventor: Michael Mutz
  • Publication number: 20120015027
    Abstract: The invention relates to the F-crystal form, G-crystal form, H-crystal form, I-crystal form and K-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans.
    Type: Application
    Filed: July 15, 2011
    Publication date: January 19, 2012
    Inventor: Michael Mutz